What top creators are saying about Walgreens Boots Alliance, Inc.(WBA)

Described as a Theranos partner persuaded by claims about its blood-testing technology. No financial impact or view on WBA shares was discussed.

Discussed in historical context regarding its commercial agreement with Theranos; no view on its current business or stock is provided.

The transcript says Walgreens had an agreement covering about 800 stores and that Evans claimed it stopped fulfilling obligations after negative Theranos coverage; no current investment outlook or recommendation is provided.

The company's legacy business model, reliant on physical stores, faces an existential threat from disruption by online, tech-enabled healthcare platforms and is considered a poor investment.

Business model is considered at risk of becoming obsolete due to disruption from telehealth companies like HIMS and e-commerce.

Explicitly called 'dead' alongside Rite Aid due to the disruption from Amazon's expansion into pharmacy services.

Mentioned as a traditional pharmacy that is struggling as consumers increasingly move to buy medications online.

Will be deleted from the S&P 500 index.

While not directly targeted by insulin price caps, the company could experience indirect, downstream effects. Changes in the pricing of high-volume drugs can potentially affect overall pharmacy revenue and margin dynamics, which is a secondary consideration for investors.